<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34183532</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-5487</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Epidemiology (Cambridge, Mass.)</Title><ISOAbbreviation>Epidemiology</ISOAbbreviation></Journal><ArticleTitle>Statin Initiation and Risk of Amyotrophic Lateral Sclerosis: A Danish Population-based Cohort Study.</ArticleTitle><Pagination><StartPage>756</StartPage><EndPage>762</EndPage><MedlinePgn>756-762</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/EDE.0000000000001384</ELocationID><Abstract><AbstractText Label="BACKGROUND">The evidence of an association between statins and amyotrophic lateral sclerosis (ALS) is heterogeneous and inconclusive.</AbstractText><AbstractText Label="METHODS">We performed a population-based cohort study consisting of 974,304 statin initiators &#x2265;40 years of age and 1,948,606 matched general population comparators identified from Danish, nationwide registries (1996-2016). We computed incidence rates and hazard ratios (HRs) of a first-time hospital-based diagnosis of ALS. HRs were controlled for sex, birth year, calendar year, medically diagnosed comorbidities, and concomitant medications.</AbstractText><AbstractText Label="RESULTS">During a median follow-up of 7.7 years, 852 ALS events occurred among statin initiators (11.3 [95% confidence interval (CI) = 10.6, 12.1] events per 100,000 person-years) and 1,679 among noninitiators (11.4 [95% CI = 10.9, 12.0] events per 100,000 person years). The overall adjusted HR indicated a slight association between statin initiation and ALS (1.11 [95% CI = 1.00, 1.23]. In the first year after initiation, the HR was 1.40 (95% CI = 1.09, 1.79) for both sexes combined, 1.00 (95% CI = 0.70, 1.42) for men, and 1.92 (95% CI = 1.30, 2.82) for women. The associations diminished to approximately null after the first year of follow-up for both sexes combined and for men, but point estimates were above 1 for women until 10 years after initiation.</AbstractText><AbstractText Label="CONCLUSIONS">Statin initiation was largely unassociated with ALS diagnosis but was associated with an elevated risk of ALS in women, especially in the first year after initiation. The association could be explained by reverse causation, detection bias, early neurotoxic effects of statins that affect women more than men, or a combination thereof.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Skajaa</LastName><ForeName>Nils</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>From the Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bakos</LastName><ForeName>Istvan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>From the Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horv&#xe1;th-Puh&#xf3;</LastName><ForeName>Erzs&#xe9;bet</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>From the Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henderson</LastName><ForeName>Victor W</ForeName><Initials>VW</Initials><AffiliationInfo><Affiliation>From the Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Population Health, Stanford University, Stanford, CA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lash</LastName><ForeName>Timothy L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Rollins School of Public Health, Emory University, GA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xf8;rensen</LastName><ForeName>Henrik Toft</ForeName><Initials>HT</Initials><AffiliationInfo><Affiliation>From the Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Population Health, Stanford University, Stanford, CA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Epidemiology</MedlineTA><NlmUniqueID>9009644</NlmUniqueID><ISSNLinking>1044-3983</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003718" MajorTopicYN="N" Type="Geographic">Denmark</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="Y">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors report no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>29</Day><Hour>5</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34183532</ArticleId><ArticleId IdType="doi">10.1097/EDE.0000000000001384</ArticleId><ArticleId IdType="pii">00001648-202109000-00020</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baigent C, Blackwell L, Emberson J, et al.; Cholesterol Treatment Trialists&#x2019; (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670&#x2013;1681.</Citation></Reference><Reference><Citation>Collaborators GBDCoD. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1151&#x2013;1210.</Citation></Reference><Reference><Citation>Mortensen MB, Falk E, Schmidt M. Twenty-year nationwide trends in statin utilization and expenditure in Denmark. Circ Cardiovasc Qual Outcomes. 2017;10:e003811.</Citation></Reference><Reference><Citation>Stroes ES, Thompson PD, Corsini A, et al.; European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36:1012&#x2013;1022.</Citation></Reference><Reference><Citation>Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97:52C&#x2013;60C.</Citation></Reference><Reference><Citation>Edwards IR, Star K, Kiuru A. Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase. Drug Saf. 2007;30:515&#x2013;525.</Citation></Reference><Reference><Citation>Colman E, Szarfman A, Wyeth J, et al. An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA&#x2019;s spontaneous adverse event reporting system. Pharmacoepidemiol Drug Saf. 2008;17:1068&#x2013;1076.</Citation></Reference><Reference><Citation>Golomb BA, Kwon EK, Koperski S, Evans MA. Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study. Drug Saf. 2009;32:649&#x2013;661.</Citation></Reference><Reference><Citation>van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084&#x2013;2098.</Citation></Reference><Reference><Citation>S&#xf8;rensen HT, Lash TL, Rothman KJ. Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies. Hepatology. 2006;44:1075&#x2013;1082.</Citation></Reference><Reference><Citation>S&#xf8;rensen HT, Riis AH, Lash TL, Pedersen L. Statin use and risk of amyotrophic lateral sclerosis and other motor neuron disorders. Circ Cardiovasc Qual Outcomes. 2010;3:413&#x2013;417.</Citation></Reference><Reference><Citation>Freedman DM, Kuncl RW, Cahoon EK, Rivera DR, Pfeiffer RM. Relationship of statins and other cholesterol-lowering medications and risk of amyotrophic lateral sclerosis in the US elderly. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:538&#x2013;546.</Citation></Reference><Reference><Citation>Seelen M, van Doormaal PT, Visser AE, et al. Prior medical conditions and the risk of amyotrophic lateral sclerosis. J Neurol. 2014;261:1949&#x2013;1956.</Citation></Reference><Reference><Citation>Mariosa D, Kamel F, Bellocco R, et al. Antidiabetics, statins and the risk of amyotrophic lateral sclerosis. Eur J Neurol. 2020;27:1010&#x2013;1016.</Citation></Reference><Reference><Citation>Golomb BA, Verden A, Messner AK, Koslik HJ, Hoffman KB. Amyotrophic lateral sclerosis associated with statin use: a disproportionality analysis of the FDA&#x2019;s adverse event reporting system. Drug Saf. 2018;41:403&#x2013;413.</Citation></Reference><Reference><Citation>Nefussy B, Hirsch J, Cudkowicz ME, Drory VE. Gender-based effect of statins on functional decline in amyotrophic lateral sclerosis. J Neurol Sci. 2011;300:23&#x2013;27.</Citation></Reference><Reference><Citation>Schmidt M, Pedersen L, S&#xf8;rensen HT. The Danish civil registration system as a tool in epidemiology. Eur J Epidemiol. 2014;29:541&#x2013;549.</Citation></Reference><Reference><Citation>Schmidt M, Schmidt SAJ, Adelborg K, et al. The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol. 2019;11:563&#x2013;591.</Citation></Reference><Reference><Citation>Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, S&#xf8;rensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449&#x2013;490.</Citation></Reference><Reference><Citation>Potteg&#xe5;rd A, Schmidt SAJ, Wallach-Kildemoes H, S&#xf8;rensen HT, Hallas J, Schmidt M. Data resource profile: the Danish National Prescription Registry. Int J Epidemiol. 2017;46:798&#x2013;798f.</Citation></Reference><Reference><Citation>Riis AH, Erichsen R, Ostenfeld EB, et al. Validating registry data on statins prescriptions by blood measurements. Pharmacoepidemiol Drug Saf. 2019;28:609&#x2013;615.</Citation></Reference><Reference><Citation>Dansk Cardiologisk Selskab. 34. Forebyggelse af hjertesygdom. Available at: https://nbv.cardio.dk/forebyggelse . Accessed 15 January 2021.</Citation></Reference><Reference><Citation>Kioumourtzoglou MA, Seals RM, Himmerslev L, Gredal O, Hansen J, Weisskopf MG. Comparison of diagnoses of amyotrophic lateral sclerosis by use of death certificates and hospital discharge data in the Danish population. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:224&#x2013;229.</Citation></Reference><Reference><Citation>Skajaa N, Sz&#xe9;pligeti SK, Horv&#xe1;th-Puh&#xf3; E, Ghanima W, Hansen JB, S&#xf8;rensen HT. Initiation of statins and risk of venous thromboembolism: population-based matched cohort study. Thromb Res. 2019;184:99&#x2013;104.</Citation></Reference><Reference><Citation>Heide-J&#xf8;rgensen U, Adelborg K, Kahlert J, S&#xf8;rensen HT, Pedersen L. Sampling strategies for selecting general population comparison cohorts. Clin Epidemiol. 2018;10:1325&#x2013;1337.</Citation></Reference><Reference><Citation>Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Statistical Assoc . 1999;94:496&#x2013;509.</Citation></Reference><Reference><Citation>Yan J, Qiao L, Tian J, et al. Effect of statins on Parkinson&#x2019;s disease: a systematic review and meta-analysis. Medicine (Baltimore). 2019;98:e14852.</Citation></Reference><Reference><Citation>Eisen A, Kiernan M, Mitsumoto H, Swash M. Amyotrophic lateral sclerosis: a long preclinical period? J Neurol Neurosurg Psychiatry. 2014;85:1232&#x2013;1238.</Citation></Reference><Reference><Citation>Thomsen RW, Nielsen RB, N&#xf8;rgaard M, et al. Lifestyle profile among statin users. Epidemiology. 2013;24:619&#x2013;620.</Citation></Reference><Reference><Citation>Kioumourtzoglou MA, Rotem RS, Seals RM, Gredal O, Hansen J, Weisskopf MG. Diabetes mellitus, obesity, and diagnosis of amyotrophic lateral sclerosis: a population-based study. JAMA Neurol. 2015;72:905&#x2013;911.</Citation></Reference><Reference><Citation>de Jong SW, Huisman MH, Sutedja NA, et al. Smoking, alcohol consumption, and the risk of amyotrophic lateral sclerosis: a population-based study. Am J Epidemiol. 2012;176:233&#x2013;239.</Citation></Reference><Reference><Citation>Dupuis L, Pradat PF, Ludolph AC, Loeffler JP. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011;10:75&#x2013;82.</Citation></Reference><Reference><Citation>Voora D, Shah SH, Spasojevic I, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 2009;54:1609&#x2013;1616.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>